How does pacritinib actually stop myelofibrosis from getting worse?
Pacritinib blocks JAK2, FLT3, and IRAK1 proteins that tell bone marrow cells to harden and stop making blood. In clinical trials, 39% of patients had their enlarged spleens shrink by 35% or more, and symptoms like fatigue and night sweats improved [1][2].
Myelofibrosis happens when a mutation in the JAK2 gene tells bone marrow cells to multiply wildly and turn the marrow into scar tissue. Pacritinib is a small pill that blocks JAK2 and related proteins, stopping that runaway signal. In the PERSIST-1 trial, 39% of pacritinib patients had meaningful spleen shrinkage versus only 1% on placebo [2].
Inside your body, pacritinib works by sitting on the JAK2 protein like a lock and key, preventing it from sending 'grow and harden' messages to bone marrow cells. It also blocks FLT3 and IRAK1, which amplify inflammation and scar-tissue formation. This dual action is why pacritinib works even when platelet counts are dangerously low—it doesn't rely on a healthy immune system to work [1][3].
The real-world trade-off is that pacritinib takes 8–12 weeks to show full benefit, and you must take it every single day. Some patients feel better in 4 weeks; others need 3 months. Your doctor will check your blood counts and liver function every 2–4 weeks at first to make sure the dose is safe for your body [9].
Ask your oncologist: 'How long until I should expect to feel better, and what blood counts should I watch for?' Mark your calendar for your first follow-up lab work—this is when your doctor decides if the dose is working or needs adjustment.